News headlines about Arrowhead Pharmaceuticals (NASDAQ:ARWR) have trended somewhat positive on Wednesday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.4809380525716 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- Trading Overview of Stock: Arrowhead Pharmaceuticals, Inc. (ARWR) – The Stocks News (press release) (thestocksnews.com)
- Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for … – Business Wire (press release) (businesswire.com)
- Hot Stock in Focus – Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) – Alpha Beta Stock (alphabetastock.com)
- Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease (finance.yahoo.com)
- Brokerages Expect Arrowhead Pharmaceuticals Inc (ARWR) Will Announce Quarterly Sales of $4.32 Million (americanbankingnews.com)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $7.64 on Wednesday. The firm has a market capitalization of $663.06, a P/E ratio of -16.26 and a beta of 2.40. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a 12-month low of $1.42 and a 12-month high of $7.93.
Several equities analysts have recently weighed in on ARWR shares. BidaskClub raised Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 18th. Cantor Fitzgerald set a $5.00 target price on Arrowhead Pharmaceuticals and gave the company a “neutral” rating in a research report on Monday, February 12th. B. Riley started coverage on Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a “neutral” rating and a $3.00 target price on the stock. Chardan Capital reissued a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. Finally, Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 target price on the stock in a research report on Monday, November 27th. Four analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $4.70.
In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the company’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $6.73, for a total value of $134,600.00. Following the transaction, the chief operating officer now owns 908,356 shares of the company’s stock, valued at approximately $6,113,235.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.60% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.